You are here
NIH-Funded ACTIV/ACTIV-Associated Clinical Trials
Company | Therapeutic | Class | Administration | New/ Repurposed |
Estimated End Date |
---|---|---|---|---|---|
ACTIV-1 Inpatient |
|||||
BMS | Orencia® (abatacept) | Immune Modulator | Intravenous | Repurposed | Q4 2021 |
Janssen | Remicade® (Infliximab) | Immune Modulator | Intravenous | Repurposed | Q4 2021 |
AbbVie | Cenicriviroc | Immune Modulator | Oral | New | Q4 2021 |
ACTIV-2 Outpatient |
|||||
AstraZeneca | AZD7442 | Monoclonal Antibody Cocktail | Intramuscular | New | Q4 2021 |
AstraZeneca | AZD7442 | Monoclonal Antibody Cocktail | Intravenous | New | Q4 2021 |
Brii Biosciences | Brii-196 & Brii-198 | Monoclonal Antibody Cocktail | Intravenous | New | Q4 2021 |
Eli Lilly | LY-CoV-555 | Monoclonal Antibody Single | Intravenous | New | Q1 2021 |
Sagent | Camostat Mesylate | Antiviral | Oral | Repurposed | Q4 2021 |
Synairgen | SNG001 IFN-beta | Immune Modulator | Inhaled | Repurposed | Q4 2021 |
ACTIV-3 Inpatient |
|||||
AstraZeneca | AZD7442 | Monoclonal Antibody Cocktail | Intravenous | New | Q3 2021 |
Brii Biosciences | Brii-196 & Brii-198 | Monoclonal Antibody Cocktail | Intravenous | New | Ended |
Eli Lilly | LY-CoV-555 | Monoclonal Antibody Single | Intravenous | New | Ended |
GSK-Vir | VIR-7831 | Monoclonal Antibody Single | Intravenous | New | Ended |
ACTIV-4 |
|||||
Outpatients |
|||||
BMS/Pfizer | Eliquis ® (apixaban) | Anticoagulant | Oral | Repurposed | Q4 2021 |
BMS/Pfizer | Aspirin | Antiplatelet | Oral | Repurposed | Q4 2021 |
Inpatients |
|||||
Other | Un-fractionated (UF) Heparin | Anticoagulant | Intravenous | Repurposed | Q2 2021 |
Other | Low Molecular Weight (LMW) Heparin | Anticoagulant | Injection | Repurposed | Q2 2021 |
ACTIV-5 Inpatient |
|||||
AbbVie/Boehringer Ingelheim | SkyrisiTM (risankizumab) | Immune Modulator | Intravenous | Repurposed | Q4 2021 |
Humanigen | Lenzilumab | Immune Modulator | Intravenous | New | Q4 2021 |
ACTIV-Associated |
|||||
Adaptive COVID-19 Treatment Trial (ACTT) Inpatient |
|||||
Gilead | Veklury® (remdesivir) | Antiviral | Intravenous | Repurposed | Q4 2020 |
Gilead/Eli Lilly | Veklury® (remdesivir) and Olumiant® (baricitinib) | Antiviral/Anti-Inflammatory | Intravenous/Oral | Repurposed | Q4 2020 |
Gilead/Eli Lilly/Other | Veklury® (remdesivir) and Olumiant® (baricitinib) or Dexamethasone | Antiviral/Anti-Inflammatory/ Immune Modulator |
Intravenous/Oral | Repurposed | Q2 2021 |
Gilead/Merck KGaA | Veklury® (remdesivir) and Rebif® (IFN-beta ) | Antiviral/Immune Modulator | Injection | Repurposed | Q1 2021 |
Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) |
|||||
Gilead/Other | Veklury® (remdesivir) and Hyperimmune Intravenous Immunoglobulin (hIVIG) |
Antiviral | Intravenous | N/A | Q3 2021 |
Convalescent Plasma in Outpatients with COVID-19 (C3PO) |
|||||
Other | Convalescent Plasma | Convalescent Plasma | Intravenous | N/A | Ended |
Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients (CONTAIN COVID-19) |
|||||
Other | Convalescent Plasma | Convalescent Plasma | Intravenous | N/A | Q2 2021 |
Passive Immunity Trial of Our Nation (PassItOn) Inpatient |
|||||
Other | Convalescent Plasma | Convalescent Plasma | Intravenous | N/A | Q2 2021 |
This page last reviewed on March 4, 2021